Search

Search Constraints

You searched for: Author/Creator Plavina, Tatiana

Search Results

1. 018  Disease control beyond NEDA: the value of non-clinical measures to determine treatment response to natalizumab. Issue 6 (27th May 2022)

3. Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab‐associated progressive multifocal leukoencephalopathy. Issue 6 (24th October 2014)

4. Blood neurofilament light levels segregate treatment effects in multiple sclerosis. (17th March 2020)

6. Changes to anti-JCV antibody levels in a Swedish national MS cohort. Issue 11 (5th March 2013)

7. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients. Issue 12 (13th October 2019)

8. Measuring treatment response to advance precision medicine for multiple sclerosis. Issue 11 (26th October 2021)

9. Neurofilament light levels are associated with long-term outcomes in multiple sclerosis. (November 2020)